Clinical Trials Logo

Clinical Trial Summary

Despite evidence regarding the benefits of physical activity in various cancer patient populations, the effects of a home-based walking program for pancreatic cancer patients have been under-explored. The aims of the proposed pilot project are to: (1) Assess the feasibility of implementing a 12-week, home-based walking program among pancreatic cancer patients; and (2) Examine the effects of a 12-week, home-based walking program on quality of life (QOL) and symptoms among pancreatic cancer patients.


Clinical Trial Description

Among cancer patients, physical activity interventions can lead to improvements in QOL and reductions in fatigue and pain. While pancreatic cancer patients may have physical restrictions that limit their participation in moderate to high-intensity exercise activities, empirical evidence suggests that even low-intensity, home-based walking programs can confer benefits for cancer patients. In this pilot study, 50 patients will be randomly assigned to receive either the walking intervention program or usual care (UC). Assessments of quality of life, distress, and symptom burden will be completed at baseline (pre-intervention) and at follow-up (i.e. within 2 weeks post-intervention or approximately 12-14 weeks post-baseline). Data from the proposed pilot study will inform the development of a larger randomized trial designed to improve QOL and reduce morbidity in this patient population. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02442323
Study type Interventional
Source Fox Chase Cancer Center
Contact
Status Completed
Phase N/A
Start date August 9, 2013
Completion date November 30, 2020

See also
  Status Clinical Trial Phase
Terminated NCT02902484 - Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT04008537 - Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device N/A
Recruiting NCT04809935 - EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy Phase 4
Not yet recruiting NCT03659292 - Effects of Epidural Block on the Prognosis in Patients With Pancreatic Cancer Undergoing Distal Pancreatectomy N/A
Completed NCT03150615 - Enteral Nutrition After Pancreaticoduodenectomy N/A
Recruiting NCT02682394 - Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas N/A
Recruiting NCT05566743 - A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas Phase 2
Not yet recruiting NCT04049461 - Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer
Recruiting NCT04164602 - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Active, not recruiting NCT04128332 - Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer N/A
Recruiting NCT03536793 - Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
Recruiting NCT02311439 - Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas Phase 2/Phase 3
Completed NCT02296736 - The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan
Withdrawn NCT04123574 - A Pilot Study of BXCL701 in Patients With Pancreatic Cancer Early Phase 1
Not yet recruiting NCT03278015 - Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT02905578 - A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) Phase 2
Completed NCT01446458 - Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer Phase 1
Recruiting NCT04677244 - Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT06148298 - Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer